Volatile organic compounds analysis optimization and biomarker discovery in urine of Non-Hodgkin lymphoma patients before and during chemotherapy

Autor(es)

Mesquita, Alessandra de Sousa ^[1] ; Zamora-Obando, Hans Rolando ^[1] ; dos Santos, Fabio Neves ^[1] ; Schmidt-Filho, Jayr ^[2] ; de Lima, Vladmir Cordeiro ^[3] ; Costa, Felipe D'Almeida ^[4] ; de Andrade, Victor Piana ^[4] ; Eberlin, Marcos Nogueira ^[5] ; Colnaghi Simionato, Ana Valeria ^{[1, 6]}

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Inst Chem, Lab Anal Biomol Tiselius LABi Tiselius, UNICAMP, Campinas, SP - Brazil

^[2] AC Camargo Canc Ctr, Dept Hematol, Sao Paulo, SP - Brazil

^[3] AC Camargo Canc Ctr, Dept Med Oncol, Sao Paulo, SP - Brazil

^[4] AC Camargo Canc Ctr, Dept Pathol, Sao Paulo, SP - Brazil

^[5] Univ Prebiteriana Mackenzie, Sch Engn PPGEMN, MackMass Lab Mass Spectrometry, Sao Paulo, SP - Brazil

^[6] Natl Inst Sci & Technol Bioanalyt INCTBio, Rio De Janeiro - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Microchemical Journal; v. 159, DEC 2020.
• Citações Web of Science: 0

Resumo

The Non-Hodgkin's lymphoma (NHL) is a severe and common neoplasm generated by metabolic changes due to cells mutations. Its prognostic or diagnosis seems therefore viable by monitoring metabolites produced and secreted into biological fluids or tissues. Hence, we used an untargeted metabolomics approach to evaluate if the profiles of volatile organic compounds (VOCs) present in urine would serve to Non-Hodgkin's lymphoma (NHL) prognostic or diagnostic. Headspace solid-phase microextraction (HS-SPME) was optimized and applied to pools of urine or serum samples from healthy patients after optimization using a Central Composite Design (CCD), followed by gas chromatography coupled to mass spectrometry (GC-MS) analysis. CCD factorial design 2(3) and the response surfaces indicated the optimized extraction parameters. Individual urine samples from healthy and diseased subjects were prepared and analyzed by the optimized method, and a thorough statistical analysis revealed several metabolites as potential biomarkers for NHL as well as able to describe the patient's metabolic profile before each chemotherapy cycle. This approach seems promising in contributing to the prognosis and choice of appropriate treatment of NHL for each individual. (AU)

• Processo FAPESP: 16/07014-5 - Determinação do perfil metabolômico de linfoma não Hodgkin para identificação de biomarcadores tumorais
• Beneficiário: Ana Valéria Colnaghi Simionato
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 17/09726-5 - Diagnóstico diferencial de Zika, Chikungunya e Dengue por espectrometria de massas de alta resolução e ion mobility
• Beneficiário: Fábio Neves dos Santos
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado